James Duncan Kellner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6742018/publications.pdf

Version: 2024-02-01

107 papers 4,754 citations

35 h-index 102487 66 g-index

108 all docs

 $\frac{108}{\text{docs citations}}$

108 times ranked 5448 citing authors

#	Article	IF	Citations
1	Impact of combination MMRV vaccine on first-dose coverage for measles and varicella: a population-based study. Zeitschrift Fur Gesundheitswissenschaften, 2022, 30, 1063-1068.	1.6	2
2	The Canadian National Vaccine Safety Network: surveillance of adverse events following immunisation among individuals immunised with the COVID-19 vaccine, a cohort study in Canada. BMJ Open, 2022, 12, e051254.	1.9	9
3	Vaccine effectiveness of the 7-valent and 13-valent pneumococcal conjugate vaccines in Canada: An IMPACT study. Vaccine, 2022, 40, 2733-2740.	3.8	10
4	Prevalence of antimicrobial resistance genes and its association with restricted antimicrobial use in food-producing animals: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2021, 76, 561-575.	3.0	30
5	Changes in Invasive Pneumococcal Disease Caused by Streptococcus pneumoniae Serotype 1 following Introduction of PCV10 and PCV13: Findings from the PSERENADE Project. Microorganisms, 2021, 9, 696.	3.6	10
6	Whole-Genome Analysis of <i>Streptococcus pneumoniae</i> Pneumococcal Disease, Alberta, Canada. Emerging Infectious Diseases, 2021, 27, 1867-1875.	4.3	9
7	Protecting Canada's children from the consequences of the fourth wave of the COVID-19 pandemic. Cmaj, 2021, 193, E1500-E1502.	2.0	1
8	PCR and Culture Analysis of Streptococcus pneumoniae Nasopharyngeal Carriage in Healthy Children. Microorganisms, 2021, 9, 2116.	3.6	10
9	Population-based incidence of invasive pneumococcal disease in children and adults in Ontario and British Columbia, 2002–2018: A Canadian Immunization Research Network (CIRN) study. Vaccine, 2021, 39, 7545-7553.	3.8	5
10	Immunogenicity of 2 and 3 Doses of the Quadrivalent Human Papillomavirus Vaccine up to 120 Months Postvaccination: Follow-up of a Randomized Clinical Trial. Clinical Infectious Diseases, 2020, 71, 1022-1029.	5.8	19
11	Investigating the association of receipt of seasonal influenza vaccine with occurrence of anesthesia/paresthesia and severe headaches, Canada 2012/13–2016/17, the Canadian Vaccine Safety Network. Vaccine, 2020, 38, 3582-3590.	3.8	5
12	2017/18 and $2018/19$ seasonal influenza vaccine safety surveillance, Canadian National Vaccine Safety (CANVAS) Network. Eurosurveillance, $2020,25,.$	7.0	9
13	Who Benefits, and How Much? Indirect Effects of Childhood Pneumococcal Vaccination in Adults at Increased Risk of Pneumococcal Disease. Clinical Infectious Diseases, 2019, 68, 1374-1375.	5.8	O
14	Homelessness in Adults With Invasive Pneumococcal Disease in Calgary, Canada. Open Forum Infectious Diseases, 2019, 6, .	0.9	19
15	Maternal perceptions of childhood vaccination: explanations of reasons for and against vaccination. BMC Public Health, 2019, 19, 49.	2.9	23
16	Examination of unintended consequences of antibiotic use restrictions in food-producing animals: Sub-analysis of a systematic review. One Health, 2019, 7, 100095.	3.4	13
17	Comparison of different approaches to antibiotic restriction in food-producing animals: stratified results from a systematic review and meta-analysis. BMJ Global Health, 2019, 4, e001710.	4.7	32
18	Barriers, supports, and effective interventions for uptake of human papillomavirus- and other vaccines within global and Canadian Indigenous peoples: a systematic review protocol. Systematic Reviews, 2018, 7, 40.	5.3	12

#	Article	IF	CITATIONS
19	Changes in the Nature and Severity of Invasive Pneumococcal Disease in Children Before and After the Seven-valent and Thirteen-valent Pneumococcal Conjugate Vaccine Programs in Calgary, Canada. Pediatric Infectious Disease Journal, 2018, 37, 22-27.	2.0	20
20	Enteropathogen detection in children with diarrhoea, or vomiting, or both, comparing rectal flocked swabs with stool specimens: an outpatient cohort study. The Lancet Gastroenterology and Hepatology, 2017, 2, 662-669.	8.1	42
21	Restricting the use of antibiotics in food-producing animals and its associations with antibiotic resistance in food-producing animals and human beings: a systematic review and meta-analysis. Lancet Planetary Health, The, 2017, 1, e316-e327.	11.4	569
22	Timeliness and completeness of routine childhood vaccinations in children by two years of age in Alberta, Canada. Canadian Journal of Public Health, 2017, 108, e124-e128.	2.3	12
23	Time to reconsider routine high-dose amoxicillin for community-acquired pneumonia in all Canadian children. Paediatrics and Child Health, 2016, 21, 65-66.	0.6	4
24	Do Dose Numbers Matter?. Pediatric Infectious Disease Journal, 2016, 35, 1242-1246.	2.0	1
25	Influence of Childhood Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Adults With Underlying Comorbidities in Calgary, Alberta (2000–2013). Clinical Infectious Diseases, 2016, 62, 1521-1526.	5.8	27
26	Prevnar 7 Childhood Immunization Program and Serotype Replacement: Changes in Pneumococcal Incidence and Resulting Impact on Health Care Costs in Alberta (2003–2008). Drugs - Real World Outcomes, 2015, 2, 153-161.	1.6	3
27	Culture and molecular-based profiles show shifts in bacterial communities of the upper respiratory tract that occur with age. ISME Journal, 2015, 9, 1246-1259.	9.8	165
28	Chickenpox: An update. Journal of Pediatric Infectious Diseases, 2015, 04, 343-350.	0.2	2
29	Alberta Provincial Pediatric EnTeric Infection TEam (APPETITE): epidemiology, emerging organisms, and economics. BMC Pediatrics, 2015, 15, 89.	1.7	35
30	Successful methodology for large-scale surveillance of severe events following influenza vaccination in Canada, 2011 and 2012. Eurosurveillance, 2015, 20, 21189.	7.0	15
31	Clinical Features and Outcomes of Serotype 19A Invasive Pneumococcal Disease in Calgary, Alberta. Canadian Journal of Infectious Diseases and Medical Microbiology, 2014, 25, e71-e75.	1.9	13
32	Rapid Online Identification of Adverse Events After Influenza Immunization in Children by PCIRN's National Ambulatory Network. Pediatric Infectious Disease Journal, 2014, 33, 1060-1064.	2.0	11
33	Trends in Asymptomatic Nasopharyngeal Colonization With Streptococcus pneumoniae After Introduction of the 13-valent Pneumococcal Conjugate Vaccine in Calgary, Canada. Pediatric Infectious Disease Journal, 2014, 33, 724-730.	2.0	42
34	Effectiveness of the standard and an alternative set of Streptococcus pneumoniae multi locus sequence typing primers. BMC Microbiology, 2014, 14, 143.	3.3	8
35	Factors Influencing Early and Late Mortality in Adults with Invasive Pneumococcal Disease in Calgary, Canada: A Prospective Surveillance Study. PLoS ONE, 2013, 8, e71924.	2.5	19
36	Social paediatrics: From 'lip service' to the health and well-being of Canada's children and youth. Paediatrics and Child Health, 2013, 18, 351-2.	0.6	4

#	Article	IF	CITATIONS
37	Empiric acyclovir for neonatal herpes simplex virus infection. Journal of Maternal-Fetal and Neonatal Medicine, 2012, 25, 1278-1282.	1.5	10
38	Safety and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers Given With Routine Pediatric Vaccinations in Canada. Pediatric Infectious Disease Journal, 2012, 31, 72-77.	2.0	48
39	Eradication of Invasive Pneumococcal Disease due to the Seven-valent Pneumococcal Conjugate Vaccine Serotypes in Calgary, Alberta. Pediatric Infectious Disease Journal, 2012, 31, e169-e175.	2.0	31
40	Safety and immunogenicity of 2010–2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12–59 months of age previously given ASO3-adjuvanted H1N12009 pandemic vaccine: A PHAC/CIHR Influenza Research Network (PCIRN) study. Vaccine, 2012, 30, 3389-3394.	3.8	15
41	Evaluation of meningococcal serogroup C conjugate vaccine programs in Canadian children: Interim analysis. Vaccine, 2012, 30, 4023-4027.	3.8	8
42	Navigating the stages of an academic career for paediatricians. Paediatrics and Child Health, 2012, 17, 301-3.	0.6	1
43	Streptococcus pneumoniaemeningitis in Alberta pre- and postintroduction of the 7-valent pneumococcal conjugate vaccine. Canadian Journal of Infectious Diseases and Medical Microbiology, 2011, 22, 137-141.	1.9	1
44	Staphylococcus aureus bloodstream infections in children: A population-based assessment. Paediatrics and Child Health, 2011, 16, 276-280.	0.6	32
45	Update on the success of the pneumococcal conjugate vaccine. Paediatrics and Child Health, 2011, 16, 233-236.	0.6	18
46	Community-Based Outbreaks in Vulnerable Populations of Invasive Infections Caused by Streptococcus pneumoniae Serotypes 5 and 8 in Calgary, Canada. PLoS ONE, 2011, 6, e28547.	2.5	38
47	Increased risk of invasive pneumococcal disease in haematological and solid-organ malignancies. Epidemiology and Infection, 2010, 138, 1804-1810.	2.1	72
48	Pneumococcal Peritonitis: Still with Us and Likely to Increase in Importance. Canadian Journal of Infectious Diseases and Medical Microbiology, 2010, 21, e23-e27.	1.9	11
49	A Systematic Review on the Diagnosis of Pediatric Bacterial Pneumonia: When Gold Is Bronze. PLoS ONE, 2010, 5, e11989.	2.5	116
50	The Challenge of Reducing Invasive Pneumococcal Disease in Indigenous Indian Populations. Clinical Infectious Diseases, 2010, 50, 1247-1248.	5.8	2
51	The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000–2007. Vaccine, 2010, 28, 2130-2136.	3.8	92
52	Regrettable lack of definition of the "well tolerated―vaccine. Vaccine, 2010, 28, 3755-3756.	3.8	0
53	Pharmacoeconomic evaluation of 10- and 13-valent pneumococcal conjugate vaccines. Vaccine, 2010, 28, 5485-5490.	3.8	43
54	Welders are at increased risk for invasive pneumococcal disease. International Journal of Infectious Diseases, 2010, 14, e796-e799.	3.3	52

#	Article	IF	CITATIONS
55	Antimicrobial Susceptibility of Invasive and Lower Respiratory Tract Isolates of Streptococcus pneumoniae, 1998 to 2007. Canadian Journal of Infectious Diseases and Medical Microbiology, 2009, 20, e139-e144.	1.9	5
56	Changing Epidemiology of Invasive Pneumococcal Disease in Canada, 1998–2007: Update from the Calgaryâ€Area <i>Streptococcus pneumoniae</i> Research (CASPER) Study. Clinical Infectious Diseases, 2009, 49, 205-212.	5.8	161
57	Dramatic pain relief and resolution of bone inflammation following pamidronate in 9 pediatric patients with persistent chronic recurrent multifocal osteomyelitis (CRMO). Pediatric Rheumatology, 2009, 7, 2.	2.1	142
58	A new genetic subgroup of chronic granulomatous disease with autosomal recessive mutations in p40phox and selective defects in neutrophil NADPH oxidase activity. Blood, 2009, 114, 3309-3315.	1.4	368
59	Serotypes and antimicrobial susceptibilities of invasive Streptococcus pneumoniae pre- and post-seven valent pneumococcal conjugate vaccine introduction in Alberta, Canada, 2000–2006. Vaccine, 2009, 27, 3553-3560.	3.8	65
60	The Changing Burden of Pediatric Bloodstream Infections in Calgary, Canada, 2000–2006. Pediatric Infectious Disease Journal, 2009, 28, 114-117.	2.0	39
61	Empyema associated with community-acquired pneumonia: A Pediatric Investigator's Collaborative Network on Infections in Canada (PICNIC) study. BMC Infectious Diseases, 2008, 8, 129.	2.9	52
62	Effects of Routine Infant Vaccination With the 7-Valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization With Streptococcus pneumoniae in Children in Calgary, Canada. Pediatric Infectious Disease Journal, 2008, 27, 526-532.	2.0	65
63	Suspected Peritonsillar Abscess in Children. Pediatric Emergency Care, 2007, 23, 431-438.	0.9	45
64	Invasive Pneumococcal Infections in Canadian Children, 1998–2003 Implications for New Vaccination Programs. Canadian Journal of Public Health, 2007, 98, 111-115.	2.3	11
65	Response to 'Benefits of glucocorticoids in the treatment of bacterial meningitis in children: End of the controversy?'. Paediatrics and Child Health, 2006, 11, 31-2.	0.6	1
66	Antibiotic choices by paediatric residents and recently graduated paediatricians for typical infectious disease problems in children. Paediatrics and Child Health, 2006, 11 , 647-53.	0.6	0
67	An Infant with Central Nervous System Complications of Disseminated Tuberculosis. Canadian Journal of Neurological Sciences, 2005, 32, 112-114.	0.5	0
68	Rotavirus gastroenteritis. Advances in Therapy, 2005, 22, 476-487.	2.9	73
69	Genital infection with human papillomavirus in adolescents. Advances in Therapy, 2005, 22, 187-197.	2.9	17
70	Hepatitis A: A preventable threat. Advances in Therapy, 2005, 22, 578-586.	2.9	7
71	Response toPseudomonas aeruginosa pre-septal cellulitis and bacteremia in a pediatric oncology patient. Pediatric Blood and Cancer, 2005, 45, 354-354.	1.5	1
72	Progress in the prevention of pneumococcal infection. Cmaj, 2005, 173, 1149-1151.	2.0	66

#	Article	IF	CITATIONS
73	Pneumococcal Serotypes in the Elderly. Clinical Infectious Diseases, 2005, 41, 488-489.	5.8	2
74	Respiratory syncytial virus bronchiolitis. Journal of the National Medical Association, 2005, 97, 1708-13.	0.8	47
75	Corticosteroids for suspected bacterial meningitis in children - Status in 2005. Paediatrics and Child Health, 2005, 10, 107-8.	0.6	1
76	Empirical Validation of Guidelines for the Management of Pharyngitis in Children and Adults. JAMA - Journal of the American Medical Association, 2004, 291, 1587.	7.4	312
77	Group A Î ² -hemolytic streptococcal pharyngitis in children. Advances in Therapy, 2004, 21, 277-287.	2.9	22
78	Acute sinusitis in children. Journal of Pediatric Health Care, 2004, 18, 72-76.	1.2	9
79	Tympanocentesis for the Management of Acute Otitis Media in Children. JAMA Pediatrics, 2004, 158, 962.	3.0	5
80	Viral croup: a current perspective. Journal of Pediatric Health Care, 2004, 18, 297-301.	1.2	7
81	A Pharmacoeconomic Evaluation of 7â€ V alent Pneumococcal Conjugate Vaccine in Canada. Clinical Infectious Diseases, 2003, 36, 259-268.	5.8	52
82	Ocular and Respiratory Symptoms Attributable to Inactivated Split Influenza Vaccine: Evidence from a Controlled Trial Involving Adults. Clinical Infectious Diseases, 2003, 36, 850-857.	5.8	43
83	Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Rate of Recurrence of Oculorespiratory Syndrome Following Influenza Vaccination among Persons Previously Affected. Clinical Infectious Diseases, 2003, 37, 1059-1066.	5.8	24
84	InvasiveStreptococcus pneumoniaeInfection Causing Hemolytic Uremic Syndrome in Children: Two Recent Cases. Canadian Journal of Infectious Diseases & Medical Microbiology, 2003, 14, 339-343.	0.3	12
85	Community-Acquired Pneumonia in Children: A Multidisciplinary Consensus Review. Canadian Journal of Infectious Diseases & Medical Microbiology, 2003, 14, 38-118.	0.3	4
86	Management of fever without source in children: Changing times. Paediatrics and Child Health, 2003, 8, 74-75.	0.6	0
87	Outcome of penicillin-nonsusceptible Streptococcus pneumoniae meningitis: a nested case-control study. Pediatric Infectious Disease Journal, 2002, 21, 903-909.	2.0	45
88	Microbiologic findings and risk factors for antimicrobial resistance at myringotomy for tympanostomy tube placement—a prospective study of 601 children in Toronto. International Journal of Pediatric Otorhinolaryngology, 2002, 66, 227-242.	1.0	18
89	Management of bacterial meningitis in children: Controversies in the management of bacterial meningitis. Paediatrics and Child Health, 2002, 7, 447-448.	0.6	0
90	Population-based, age-specific myringotomy with tympanostomy tube insertion rates in Calgary, Canada. Pediatric Infectious Disease Journal, 2002, 21, 348-350.	2.0	19

#	Article	IF	CITATIONS
91	Beliefs and Behaviours of Parents Regarding Antibiotic Use by Children. Canadian Journal of Infectious Diseases & Medical Microbiology, 2001, 12, 93-97.	0.3	13
92	Acute infectious conjunctivitis in childhood. Paediatrics and Child Health, 2001, 6, 329-335.	0.6	14
93	Drug-resistant Streptococcus pneumoniae infections: Clinical importance, drug treatment, and preventionâ [†] t. Seminars in Respiratory Infections, 2001, 16, 186-195.	1.3	13
94	A Novel Multiresistant <i>Streptococcus pneumoniae</i> Serogroup 19 Clone from Washington State Identified by Pulsed-Field Gel Electrophoresis and Restriction Fragment Length Patterns. Journal of Clinical Microbiology, 2000, 38, 1575-1580.	3.9	18
95	Household Transmission of <i>Streptococcus pneumoniae, </i> Alberta, Canada. Emerging Infectious Diseases, 1999, 5, 154-158.	4.3	8
96	Antibiotic Prescribing for Canadian Preschool Children: Evidence of Overprescribing for Viral Respiratory Infections. Clinical Infectious Diseases, 1999, 29, 155-160.	5.8	140
97	Streptococcus pneumoniae Carriage in Children Attending 59 Canadian Child Care Centers. JAMA Pediatrics, 1999, 153, 495.	3.0	102
98	Superbugs: How they evolve and minimize the cost of resistance. Current Infectious Disease Reports, 1999, 1, 464-469.	3.0	11
99	The effectiveness of glucocorticoids in treating croup: meta-analysis. BMJ: British Medical Journal, 1999, 319, 595-600.	2.3	119
100	The superbugs: evolution, dissemination and fitness. Current Opinion in Microbiology, 1998, 1, 524-529.	5.1	46
101	Predictors and Outcome of Admission for Invasive Streptococcus pneumoniae Infections at a Canadian Children's Hospital. Clinical Infectious Diseases, 1998, 27, 597-602.	5.8	12
102	Prevalence and Characterization of the Mechanisms of Macrolide, Lincosamide, and Streptogramin Resistance in Isolates of <i>Streptococcus pneumoniae</i> . Antimicrobial Agents and Chemotherapy, 1998, 42, 2425-2426.	3.2	193
103	The use of Streptococcus pneumoniae nasopharyngeal isolates from healthy children to predict features of invasive disease. Pediatric Infectious Disease Journal, 1998, 17, 279-286.	2.0	89
104	Efficacy of Bronchodilator Therapy in Bronchiolitis. JAMA Pediatrics, 1996, 150, 1166.	3.0	144
105	Association of Ureaplasma urealyticum colonization with chronic lung disease of prematurity: Results of a metaanalysis. Journal of Pediatrics, 1995, 127, 640-644.	1.8	186
106	Analgesia in Children with Sickle Cell Crisis: Comparison of Intermittent Opioids Vs. Continuous Intravenous Infusion of Morphine and Placebo-Controlled Study of Oxygen Inhalation. Pediatric Hematology and Oncology, 1992, 9, 317-326.	0.8	69
107	Oxygen Therapy in Sickle Cell Disease. Journal of Pediatric Hematology/Oncology, 1992, 14, 222-228.	0.6	36